Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Processa Pharmaceuticals Inc (PCSA)

Processa Pharmaceuticals Inc (PCSA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 145,286
  • Shares Outstanding, K 15,522
  • Annual Sales, $ 0 K
  • Annual Income, $ -14,410 K
  • 60-Month Beta 0.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.33
Trade PCSA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.25 +0.10%
on 04/15/21
14.24 -34.98%
on 03/19/21
-2.32 (-20.04%)
since 03/15/21
3-Month
5.86 +58.01%
on 01/27/21
14.24 -34.98%
on 03/19/21
+2.49 (+36.77%)
since 01/15/21
52-Week
3.40 +172.33%
on 10/02/20
14.24 -34.98%
on 03/19/21
-0.74 (-7.41%)
since 03/31/20

Most Recent Stories

More News
Processa Pharmaceuticals Announces Year end 2020 Results and Provides Corporate Update

Clinical drug pipeline is funded and targeting major milestones in 2021

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals Schedules Conference Call to Discuss Fourth Quarter Results and Provide Drug Development Update on March 25 at 5:30 p.m. ET

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients...

PCSA : 9.26 (-1.07%)
Processa Announces Sites Selected for Phase 2B Clinical Trial to Treat Patients with Ulcerated Necrobiosis Lipoidica

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ("Processa" or the "Company"), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options...

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals Announces Closing of a $10.2 Million Private Placement

Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is pleased to announce it has closed its previously announced private placement to institutional and accredited investors of $10.2 million. The Company sold...

PCSA : 9.26 (-1.07%)
Encode Ideas, L.P. Announces the Initiation of Research Coverage on Processa Pharmaceuticals, Inc.

Dover, Delaware--(Newsfile Corp. - February 22, 2021) - Encode Ideas, L.P. Initiates Research on Processa Pharmaceuticals, Inc. (NASDAQ: PCSA). The full research publication is available and available...

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals Announces $10.2 Million Strategic Financing

Strengthened Financial Position Supports Execution Through 2023

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients...

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences

via InvestorWire - Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of...

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update

via InvestorWire -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) ("Processa" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of drug products that are intended...

PCSA : 9.26 (-1.07%)
Processa Pharmaceuticals Announces the Appointment of Dr. Khalid Islam to Its Board of Directors

Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), ("Processa" or the "Company"), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients...

PCSA : 9.26 (-1.07%)
FENC : 6.41 (-0.62%)
IMMU : 87.86 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Processa Pharmaceuticals, Inc. is focused on the development of drug products which intended to improve the survival and/or quality of life for patients who have unmet medical need. Processa Pharmaceuticals Inc., formerly known as Heatwurx Inc., is based in HANOVER, United States.

See More

Key Turning Points

3rd Resistance Point 10.17
2nd Resistance Point 9.99
1st Resistance Point 9.67
Last Price 9.26
1st Support Level 9.17
2nd Support Level 8.99
3rd Support Level 8.67

See More

52-Week High 14.24
Fibonacci 61.8% 10.10
Last Price 9.26
Fibonacci 50% 8.82
Fibonacci 38.2% 7.54
52-Week Low 3.40

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar